These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3145998)

  • 1. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
    Kamiya T
    Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
    [No Abstract]   [Full Text] [Related]  

  • 2. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 3. [Improvement in anti-hemophilic preparations and its problems. 3. Treatment of hemophilia patients with inhibitors; induction of immune tolerance by a low or intermediate dose regimen].
    Iizuka A
    Rinsho Ketsueki; 1988 May; 29(5):640-8. PubMed ID: 3145995
    [No Abstract]   [Full Text] [Related]  

  • 4. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

  • 5. Blood safety and the choice of anti-hemophilic factor concentrate.
    Janco RL
    Pediatr Blood Cancer; 2007 Jan; 48(1):117. PubMed ID: 17063470
    [No Abstract]   [Full Text] [Related]  

  • 6. [Improvement in anti-hemophilic preparations and its problems. 4. Factor VIII preparation (RCG-5) with intermediate purity and potency].
    Yoshioka A
    Rinsho Ketsueki; 1988 May; 29(5):649-54. PubMed ID: 3145996
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of antibodies to LAV/HTLV III in hemophiliacs with the use of virus-inactivated clotting factors.
    Dietz B; Klose HJ; Gürtler L; Eberle J; Deinhardt F; Köhler-Vajta K; Peller P
    Thromb Haemost; 1986 Aug; 56(1):50-2. PubMed ID: 3095947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Technic of obtaining the antihemophilic factors VIII and IX and their clinical application].
    Triginer J; Vila M; Vicente Arangüena P
    Sangre (Barc); 1979; 24(5-C):937-41. PubMed ID: 121169
    [No Abstract]   [Full Text] [Related]  

  • 9. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex.
    Schimpf K; Schwarz P; Kunschak M
    Thromb Haemost; 1995 Mar; 73(3):553-5. PubMed ID: 7667845
    [No Abstract]   [Full Text] [Related]  

  • 10. Modern treatment of hemophilia: from the shadows towards the light.
    Mannucci PM
    Thromb Haemost; 1993 Jul; 70(1):17-23. PubMed ID: 8236096
    [No Abstract]   [Full Text] [Related]  

  • 11. [Improvement in anti-hemophilic preparations and its problems. 5. Stability and oral administration of factor VIII and IX concentrates].
    Oguma Y; Shimizu K; Sakuragawa N
    Rinsho Ketsueki; 1988 May; 29(5):655-61. PubMed ID: 3145997
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiologic considerations in the management of hemophilia.
    Briggs DK
    Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
    [No Abstract]   [Full Text] [Related]  

  • 14. Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance.
    Reipert BM; Sasgary M; Ahmad RU; Auer W; Turecek PL; Schwarz HP
    Thromb Haemost; 2001 Dec; 86(6):1345-52. PubMed ID: 11776297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and pasteurised factor VIII and IX concentrates.
    Klarmann D; Kreuz W; Auerswald G; Auberger K; Rabenau H; Gürtler L; Roggendorf M
    Thromb Haemost; 1995 Apr; 73(4):736-7. PubMed ID: 7495095
    [No Abstract]   [Full Text] [Related]  

  • 17. Factor VIII:C purified from plasma via monoclonal antibodies: human studies.
    Levine PH
    Semin Hematol; 1988 Apr; 25(2 Suppl 1):38-41. PubMed ID: 2968653
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status and trends in the treatment of hemophilic patients with inhibitors.
    Bloom AL
    Prog Clin Biol Res; 1981; 72():123-38. PubMed ID: 6801682
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoclonal antibodies to human procoagulant factor VIII.
    Rotblat F; Goodall AH; O'Brien DP; Rawlings E; Middleton S; Tuddenham EG
    J Lab Clin Med; 1983 May; 101(5):736-46. PubMed ID: 6403638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cellular immunology status in 5 hemophilic patients with inhibitors subjected to massive therapy with factor VIII concentrate].
    Aznar JA; Jorquera JI; González Molina A; Carbonell F; Trenor A; Sánchez Cuenca JM; de Andrés R
    Sangre (Barc); 1983; 28(5):663-4. PubMed ID: 6420915
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.